ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Vitruvias, Sinotherapeutics launch approved version of Propafenone ER in the U.S.
March 12, 2019Rythmol SR, known generically as propafenone hydrochloride, is an antiarrhythmic drug supplied in extended-release capsules of 225, 325 and 425 mg for oral administration -
Vitruvias Therapeutics Inc. Launches Shanghai-Based Sinotherapeutics’s Approved Version of Propafenone ER in the U.S.
March 12, 2019Vitruvias Therapeutics Inc., an Auburn, Alabama-based finished-dose generic drug company, and Sinotherapeutics Inc., a Shanghai-based generic drug company, announced they have launched a bioequivalent FDA-approved version of Rythmol SR.
Pharma Sources Insight January 2025
